Emergent BioSolutions (EBS) Cash & Equivalents (2010 - 2026)
Emergent BioSolutions (EBS) posted Cash & Equivalents of $139.7 million for Q2 2026, down 12.85% on a QoQ basis from $160.3 million in Q1 2026, and down 47.74% year-over-year from $267.3 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Cash & Equivalents (2010 - 2026) Analysis & Trends
Emergent BioSolutions has reported Cash & Equivalents for 17 years, with the latest figure at $139.7 million in Q2 2026.
- On a quarterly basis, Cash & Equivalents fell 47.74% year-over-year to $139.7 million in Q2 2026; TTM through Jun 2026 was $139.7 million, a 47.74% decrease from a year earlier, with the FY2025 full-year figure at $205.4 million, up 106.43% from the prior year.
- Cash & Equivalents was $139.7 million for Q2 2026 at Emergent BioSolutions, down from $160.3 million in the prior quarter.
- The five-year high for Cash & Equivalents was $642.6 million in Q4 2022, with the low at $69.7 million in Q2 2024.
- Average Cash & Equivalents over 5 years is $220.0 million, with a median of $155.1 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents sank 82.62% in 2023, then soared 283.5% in 2025.
- Over 5 years, Cash & Equivalents stood at $642.6 million in 2022, then tumbled by 82.62% to $111.7 million in 2023, then fell by 10.92% to $99.5 million in 2024, then soared by 106.43% to $205.4 million in 2025, then tumbled by 31.99% to $139.7 million in 2026.
- The last three Cash & Equivalents figures came in at $139.7 million (Q2 2026), $160.3 million (Q1 2026), and $205.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | 976.00 Mn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | 8.72 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | 7.38 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 5.10 Bn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 815.44 Mn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | 139.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 139.70 Mn |
| Mar 31, 2026 | 160.30 Mn |
| Dec 31, 2025 | 205.40 Mn |
| Sep 30, 2025 | 245.50 Mn |
| Jun 30, 2025 | 267.30 Mn |
| Mar 31, 2025 | 149.10 Mn |
| Dec 31, 2024 | 99.50 Mn |
| Sep 30, 2024 | 149.90 Mn |
| Jun 30, 2024 | 69.70 Mn |
| Mar 31, 2024 | 78.50 Mn |
| Dec 31, 2023 | 111.70 Mn |
| Sep 30, 2023 | 87.80 Mn |
| Jun 30, 2023 | 88.60 Mn |
| Mar 31, 2023 | 430.20 Mn |
| Dec 31, 2022 | 642.60 Mn |
| Sep 30, 2022 | 240.90 Mn |
| Jun 30, 2022 | 358.10 Mn |
| Mar 31, 2022 | 435.80 Mn |
| Dec 31, 2021 | 576.10 Mn |
| Sep 30, 2021 | 403.80 Mn |
API Access
Emergent BioSolutions Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();